Home>>Signaling Pathways>> Others>> Others>>TM-25659
TM-25659 Catalog No.GC33782

Size Price Stock Qty
10mM*1mLinDMSO
$354.00
In stock
5mg
$321.00
In stock
10mg
$506.00
In stock
25mg
$1,011.00
In stock
50mg
$1,655.00
In stock
100mg
$2,574.00
In stock

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Chemical Properties

Cas No. 260553-97-7 SDF Download SDF
Synonyms N/A
Chemical Name N/A
Canonical SMILES CC1=C(C2=CC=CN=C2)C=C3C(N(CC4=CC=C(C5=CC=CC=C5C6=NN=NN6)C=C4)C(CCCC)=N3)=N1
Formula C30H28N8 M.Wt 500.6
Solubility DMSO : ≥ 135 mg/mL (269.68 mM);H2O : < 0.1 mg/mL (insoluble) Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

Background

TM-25659 is a TAZ modulator. Anti-osteoporotic and anti-obesity activities[1].

TM-25659 (2, 10, 20, 100 μM) enhances nuclear TAZ localization in a dose-dependent manner and attenuates PPARγ-mediated adipocyte differentiation by facilitating PPARγ suppression activity of TAZ[1].TM-25659 (2, 10, 50 μM) enhances osteogenic gene expression and thereby increases osteoblast differentiation[1].|| Cell Proliferation Assay[1]||Cell Line:|3T3-L1 cells|Concentration:|2, 10, 20, 100 μM|Incubation Time:|6 days|Result:|TM-25659 acted as a suppressor of PPARγ-dependent adipocyte differentiation[1].

TM-25659 (50 mg/kg, i.p., every other day for 2 weeks) suppresses bone loss in vivo and decreases weight gain in an obesity model[1].TM-25659 has a favourable pharmacokinetic profile in rats. The plasma concentration of TM-25659 declines with an approximate t1/2 of 7 or 10 h following i.v or p.o. administration respectively. The systemic clearance (CL) is 0.21 L×h-1×kg-1 and the volume of distribution at steady-state (1.91 L×h-1×kg-1) is larger than the volume of total body fluids[1].|| Animal Model:|C57BL6 mice (4- to 6-week-old )[1]|Dosage:|50 mg/kg|Administration:|i.p., every other day for 2 weeks|Result:||| Animal Model:|Adult male Sprague-Dawley rats[1]|Dosage:|10 mg/kg|Administration:|i.v (2, 10 and 30 min), oral (15 and 30 min, and 1, 2, 4 and 8 h)|Result:|

[1]. Jang EJ, et al. TM-25659 enhances osteogenic differentiation and suppresses adipogenic differentiation by modulating the transcriptional co-activator TAZ. Br J Pharmacol. 2012 Mar;165(5):1584-94.